

Appendix 4: Criteria for triple therapy and for triple inhaler use in COPD

This appendix was approved by the Respiratory Clinical Network on 07/06/2018 and:

- Emphasises the importance of high-impact low-cost interventions for all (flu vaccination, smoking cessation support, pulmonary rehabilitation referral) and of inhaler technique check and self-management plans.
- Reinforces the indications for triple therapy with LAMA/LABA/ICS in COPD.
- Defines the roles of the new triple therapy inhalers, Trelegy and Trimbow, which have recently been approved by the Area Prescribing Committee for the city-wide COPD inhaler formulary.
- **Emphasises that triple therapy should:**
 - **Only be used where indicated.**
 - **Stepped down when not indicated.**

See flow sheet below:

